en

PRODUCT DETAIL

XELJANZ 11 mg tablety s predĺženým uvoľňovaním

Code 3286D
MA number EU/1/17/1178/011
Product Form: tbl plg 90x11 mg (fľ.HDPE)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
MAH, country: Pfizer Europe MA EEIG, Belgium
Therapeutic Class: 59 - IMMUNOPRAEPARATA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 Immunosuppressants
L04A Immunosuppressants
L04AA Selective immunosuppressants
L04AA29 Tofacitinib
Shelf life: 36
Route of admin.: Oral use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 8(3) application - new active substance
MA issued: 22.03.2017
Validity: 24.03.2027
SmPC + PL: European Medicines Agency's database
Dokument: XELJANZ Karta pre pacienta.pdf  
Dokument: XELJANZ Kontrolný zoznam k priebehu liečby.pdf  
Dokument: XELJANZ Kontrolný zoznam k začiatku liečby.pdf  
Dokument: XELJANZ Prirucka pre lekara.pdf  
Safety feature Yes
Data update: 29.03.2023
eu-flag.png sk-flag.png